R.SR
REGISTERED-SUPPLEMENTAL REGISTER
10/19/2021
Back to search
Official data from USPTO
RED CELL THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
RED CELL THERAPEUTICS
ST13
US500000088807844Class
5
Filing
88807844
Registration
6532454
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
10/19/2021
Trademark type
Word
Nice classes
5
Filing date
02/24/2020
Registration date
10/19/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/19/2021
Last transaction
10/19/2021
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Supplemental Register
Filing basis
Intent to use
First use anywhere
11/11/2020
First use in commerce
11/11/2020
Drawing code
4
Owner type
03
Owner location
Cambridge, MA
Examiner
FALK, JONATHAN ROBERT
Law office
M20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Rubius Therapeutics, Inc.
Representatives
CHRISTINA M. LICURSI WOLF, GREENFIELD & SACKS, P.C.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Cells for medical or clinical use for the treatment of a variety of human diseases and conditionscancerinflammatory diseases and disordersautoimmune diseases and disordersmetabolic diseases and disordersgenetic diseases and disordersinfectious diseases and disorderscardiovascular diseases and disordersneurological diseases and disordershematological diseases and disordersdermatological diseases and disordersophthalmological diseases and disordersgastrointestinal diseases and disordersgenitourinary diseases and disordersrenal diseases and disordersrespiratory diseases and disordersconnective tissues diseases and disordersenzyme deficiency diseases and disorders; pharmaceutical preparations of engineered erythroid cells for medical or clinical use for the treatment of a variety of human diseases and conditionscancerinflammatory diseases and disordersautoimmune diseases and disordersmetabolic diseases and disordersgenetic diseases and disordersinfectious diseases and disorderscardiovascular diseases and disordersneurological diseases and disordershematological diseases and disordersdermatological diseases and disordersophthalmological diseases and disordersgastrointestinal diseases and disordersgenitourinary diseases and disordersrenal diseases and disordersrespiratory diseases and disordersconnective tissues diseases and disordersenzyme deficiency diseases and disorders; engineered erythroid cells for medical or clinical use for the treatment of a variety of human diseases and conditionscancerinflammatory diseases and disordersautoimmune diseases and disordersmetabolic diseases and disordersgenetic diseases and disordersinfectious diseases and disorderscardiovascular diseases and disordersneurological diseases and disordershematological diseases and disordersdermatological diseases and disordersophthalmological diseases and disordersgastrointestinal diseases and disordersgenitourinary diseases and disordersrenal diseases and disordersrespiratory diseases and disordersconnective tissues diseases and disordersenzyme deficiency diseases and disorders; none of the foregoing used as vitamin-mineral supplements or for animals
Publications
History of USPTO decisions and trademark events.
30 publications found
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
09/15/2021
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
09/07/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
09/07/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/07/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
09/07/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/07/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/21/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/20/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/20/2021
AAUA
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
02/09/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/06/2021
GNRT
NON-FINAL ACTION E-MAILED
02/06/2021
CNRT
NON-FINAL ACTION WRITTEN
02/06/2021
IUAA
USE AMENDMENT ACCEPTED
02/06/2021
AUPC
AMENDMENT TO USE PROCESSING COMPLETE
01/12/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/20/2020
IUAF
USE AMENDMENT FILED
11/19/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/19/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/19/2020
EAAU
TEAS AMENDMENT OF USE RECEIVED
11/19/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/20/2020
GNRT
NON-FINAL ACTION E-MAILED
05/20/2020
CNRT
NON-FINAL ACTION WRITTEN
05/20/2020
DOCK
ASSIGNED TO EXAMINER
05/13/2020
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
03/21/2020
ALIE
ASSIGNED TO LIE
03/13/2020
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
03/06/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/27/2020
NWAP
NEW APPLICATION ENTERED
02/27/2020
Continuous trademark protection
Get notified about every new filing that threatens RED CELL THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.